Prediction models for vaccine immunogenicity are mathematical and computational tools used to forecast how well a vaccine will provoke an immune response. These models take into account various factors, such as the type of antigen, the delivery method, and the characteristics of the immune system, to predict the likelihood that a vaccine will generate a protective immune response. Such models are essential for optimizing vaccine development, as they can help identify promising candidates early in the process, reducing the time and cost of trials. By integrating data from clinical trials, immunological studies, and genomic research, prediction models allow researchers to fine-tune vaccine formulations for maximum efficacy. In addition to predicting immunogenicity, these models can also be used to assess potential side effects or adverse reactions, helping ensure the safety of vaccines before they are approved for widespread use. They represent a crucial step in accelerating vaccine development and improving vaccine outcomes.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States